692 related articles for article (PubMed ID: 25590800)
21. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
Tanos R; Karmali D; Nalluri S; Goldsmith KC
BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
[TBL] [Abstract][Full Text] [Related]
22. Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis.
Shen Q; Li J; Mai J; Zhang Z; Fisher A; Wu X; Li Z; Ramirez MR; Chen S; Shen H
Cell Death Dis; 2018 Sep; 9(10):986. PubMed ID: 30250075
[TBL] [Abstract][Full Text] [Related]
23. Evaluation and critical assessment of putative MCL-1 inhibitors.
Varadarajan S; Vogler M; Butterworth M; Dinsdale D; Walensky LD; Cohen GM
Cell Death Differ; 2013 Nov; 20(11):1475-84. PubMed ID: 23832116
[TBL] [Abstract][Full Text] [Related]
24. Binding affinity of pro-apoptotic BH3 peptides for the anti-apoptotic Mcl-1 and A1 proteins: Molecular dynamics simulations of Mcl-1 and A1 in complex with six different BH3 peptides.
Modi V; Sankararamakrishnan R
J Mol Graph Model; 2017 May; 73():115-128. PubMed ID: 28279820
[TBL] [Abstract][Full Text] [Related]
25. Aspirin overcomes Navitoclax-resistance in hepatocellular carcinoma cells through suppression of Mcl-1.
Li G; Zhang S; Fang H; Yan B; Zhao Y; Feng L; Ma X; Ye X
Biochem Biophys Res Commun; 2013 May; 434(4):809-14. PubMed ID: 23611778
[TBL] [Abstract][Full Text] [Related]
26. Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins.
Tanaka Y; Aikawa K; Nishida G; Homma M; Sogabe S; Igaki S; Hayano Y; Sameshima T; Miyahisa I; Kawamoto T; Tawada M; Imai Y; Inazuka M; Cho N; Imaeda Y; Ishikawa T
J Med Chem; 2013 Dec; 56(23):9635-45. PubMed ID: 24215352
[TBL] [Abstract][Full Text] [Related]
27. Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263.
Shao H; Jing K; Mahmoud E; Huang H; Fang X; Yu C
Mol Cancer Ther; 2013 Dec; 12(12):2640-50. PubMed ID: 24126433
[TBL] [Abstract][Full Text] [Related]
28. Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers.
Modugno M; Banfi P; Gasparri F; Borzilleri R; Carter P; Cornelius L; Gottardis M; Lee V; Mapelli C; Naglich JG; Tebben A; Vite G; Pastori W; Albanese C; Corti E; Ballinari D; Galvani A
Exp Cell Res; 2015 Mar; 332(2):267-77. PubMed ID: 25486070
[TBL] [Abstract][Full Text] [Related]
29. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak.
Sun JG; Xiang J; Zeng XL; Li X; Wu P; Fung KP; Liu FY
Cancer Lett; 2014 Dec; 355(2):253-63. PubMed ID: 25304383
[TBL] [Abstract][Full Text] [Related]
30. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
Wan Y; Dai N; Tang Z; Fang H
Eur J Med Chem; 2018 Feb; 146():471-482. PubMed ID: 29407973
[TBL] [Abstract][Full Text] [Related]
31. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1.
Zhang S; Li G; Ma X; Wang Y; Liu G; Feng L; Zhao Y; Zhang G; Wu Y; Ye X; Qin B; Lu J
Cell Signal; 2012 Sep; 24(9):1803-9. PubMed ID: 22609455
[TBL] [Abstract][Full Text] [Related]
32. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling.
Peperzak V; Slinger E; Ter Burg J; Eldering E
Cell Death Differ; 2017 Jan; 24(1):111-119. PubMed ID: 27689871
[TBL] [Abstract][Full Text] [Related]
33. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.
Chen J; Jin S; Abraham V; Huang X; Liu B; Mitten MJ; Nimmer P; Lin X; Smith M; Shen Y; Shoemaker AR; Tahir SK; Zhang H; Ackler SL; Rosenberg SH; Maecker H; Sampath D; Leverson JD; Tse C; Elmore SW
Mol Cancer Ther; 2011 Dec; 10(12):2340-9. PubMed ID: 21914853
[TBL] [Abstract][Full Text] [Related]
34. First MCL-1-selective BH3 mimetics as potential therapeutics for targeted treatment of cancer.
Besbes S; Billard C
Cell Death Dis; 2015 Jul; 6(7):e1810. PubMed ID: 26158516
[No Abstract] [Full Text] [Related]
35. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo.
Bai L; Chen J; McEachern D; Liu L; Zhou H; Aguilar A; Wang S
PLoS One; 2014; 9(6):e99404. PubMed ID: 24901320
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
37. Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling.
Grundy M; Seedhouse C; Jones T; Elmi L; Hall M; Graham A; Russell N; Pallis M
PLoS One; 2018; 13(1):e0190682. PubMed ID: 29298347
[TBL] [Abstract][Full Text] [Related]
38. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
[TBL] [Abstract][Full Text] [Related]
39. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y
Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063
[TBL] [Abstract][Full Text] [Related]
40. Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer.
Nakajima W; Sharma K; Hicks MA; Le N; Brown R; Krystal GW; Harada H
Cancer Biol Ther; 2016; 17(1):27-35. PubMed ID: 26575826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
